Nuveen Asset Management, LLC Summit Therapeutics Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 234,426 shares of SMMT stock, worth $6.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

234,426

Previous 269,755 13.1%

Holding current value

$6.72 Million

Previous $5.91 Million 29.17%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$17.52 - $23.46 $618,964 - $828,818	-35,329 Reduced 13.1%	234,426 $4.18 Million
Q3 2024 Nov 14, 2024	SELL	$6.89 - $31.93 $47,795 - $221,498	-6,937 Reduced 2.51%	269,755 $5.91 Million
Q2 2024 Aug 09, 2024	SELL	$2.39 - $10.92 $222,826 - $1.02 Million	-93,233 Reduced 25.2%	276,692 $2.16 Million
Q1 2024 May 13, 2024	SELL	$2.55 - $5.07 $499,032 - $992,193	-195,699 Reduced 34.6%	369,925 $1.53 Million
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.83 $293,714 - $497,731	175,877 Added 45.13%	565,624 $1.48 Million
Q2 2023 Aug 14, 2023	BUY	$1.32 - $2.81 $514,466 - $1.1 Million	389,747 New	389,747 $978,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.38 $50,368 - $130,300	-54,748 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.0 - $3.45 $22,590 - $38,967	-11,295 Reduced 17.1%	54,748 $178,000
Q4 2021 Feb 14, 2022	SELL	$2.45 - $5.64 $21,746 - $50,060	-8,876 Reduced 11.85%	66,043 $303,000
Q3 2021 Nov 12, 2021	BUY	$4.83 - $8.27 $132,448 - $226,779	27,422 Added 57.73%	74,919 $478,000
Q2 2021 Aug 16, 2021	BUY	$5.15 - $8.46 $244,609 - $401,824	47,497 New	47,497 $354,000

Others Institutions Holding SMMT

# of Institutions

246

Shares Held

87.3M

Call Options Held

1.77M

Put Options Held

2.49M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $5.77B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Summit Therapeutics Inc. Transaction History